Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00573521 · ClinicalTrials.gov registry record

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

A clinical trial, sponsored by University of Pittsburgh.

Completed
Registry status
450
Enrollment target

NCT00573521: Completed study, sponsored by University of Pittsburgh.

NCT00573521 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 450 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00573521 has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
450 participants
Enrollment target

Study Summary

This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2007-11
Est. Completion 2017-06
University of Pittsburgh

1,238 total trials

What the finished NCT00573521 record still lists

NCT00573521 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00573521 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00573521 about?

NCT00573521 is a clinical study titled "Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms". This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.

What is the current status of trial NCT00573521?

This trial is currently completed. The enrollment target is 450 participants. The study started on 2007-11. Estimated completion is 2017-06.

Who is sponsoring clinical trial NCT00573521?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00573521, the US trial registry maintained by the National Library of Medicine. NCT00573521 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.